skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I HAVE HELD THESE STOCKS FOR ALMOST YEAR AND A HALF, HOPING THE STOCKS WILL MOVE UP AS THE VACCINES BECOME AVAILABLE. I FIND THAT NONE OF THESE STOCKS HAVE MOVED UP EXCEPT VEEV, AND THAT TOO MARGINALLY. SHOULD I KEEP THESE STOCKS OR SELL THEM AND USE THE MONEY FOR OTHER PROMISING TECH STOCKS. THANKS
Read Answer Asked by Vinod on December 10, 2020
Q: I have a DOY balanced portfolio (Alpha-Balanced for guidance) , with less than 10 year timeframe.
I’m underweight communication services, and energy. Not a fan at this stage of oil or precious metals. Overweight in industrials and technology.
My concern is with my overweight in technology. Reading a number of opinion articles that refer to the tech boom as another dot.com. The reply often is oh but this is different.
Here’s my two cents worth especially related to tech stocks I own. First of all investors/traders seem to be jumping in and out of technology based on the latest COVID-19 / vaccine news.
Re KXS; will still be in demand long after Covid-19. LSPD; somewhat sensitive to Covid-19 but have done a good job diversifying and adapting restaurant services etc. Will do well in recovery.
Maybe more acquisitions.
SHOP; like Amazon will carry on even though the valuation is high. Younger generation will still shop on line.
Now comes the tricky part. WELL and VEEV. I don’t quite have a handle on. Not sure if the demand for their service will still be there post COVID-19.
Your comments and/or thought would be greatly appreciated. I have a feeling that many of your clients would be interested in what you have to say.
I’m an experienced investor but don’t have access to the kinds of info I once did. I depend a great deal on your unbiased expert opinion.
Merry Christmas

Roy
Read Answer Asked by Roy on December 10, 2020
Q: Atara Biotherapeutics (NASDAQ:ATRA) has announced presentation of preclinical data of ATA3219 at American Society of Hematology.
Their allogeneic CAR T-cell therapy targeting CD19, Bayer has also just entered into an exclusive worldwide license agreement, for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors with Atara.
What is your opinion on this company and it's medium and long term investment potential.
Read Answer Asked by Rajesh on December 10, 2020
Q: Good morning, I have a watch-list of vaccines, but it seemed like such a gamble in the past months, I didn't invest in any. Now that some are successful, I would like to have a position in at least one company. I've named a few above, but there are more. With the goal of growth in the next 1-2 years, which one or two "vaccine" stocks would you choose, and what percentage of the portfolio would you suggest as investment size. Thank-you.
Read Answer Asked by Kim on December 09, 2020
Q: Hi there,

DMTK I came across DermTech listening to a MF US stock advisor live session on 10X opportunities. I spent some time reviewing their most recent earnings transcript and other research and the technology for non invasive detection of skin cancer seems powerful but super early in terms of adoption (a brief excerpt is below). I am considering buying for TFSA and have the following questions:
1. What is your general opinion?
2. Do you have any information on how a dermatologist would be paid for using this test vs surgery? My fear would be that the tech is amazing but dermatologists may not use it if it would reduce their revenue

"Currently, approximately 25 surgical biopsies are performed to find one melanoma. And despite all this cutting, the negative predictive value of this pathway is only about 83%, which means the probability of missing melanoma is approximately 17%. The PLA reduces the number of surgical biopsies needed to identify melanomas by approximately 10-fold and increases the negative predictive value so 99%, meaning the PLA has less than 1% probability of missing the disease. DermTech is effectively bringing melanoma diagnosis into the 21st century by transforming it from a pathway to subjective, invasive, inaccurate and costly to one that is objective, non-invasive, highly accurate, and less costly."
Read Answer Asked by Tim on December 08, 2020
Q: Hi,

Of these relatively new biotech companies that have or will soon be IPO'ing, Repare Therapeutics (June IPO) and Abcellera Biotech (upcoming IPO), where would you put some play money? A bit of both? Or another recent IPO/choice altogether?
It seems that Abcellera might be a little ahead of the game wrt being profitable already. And I'm pretty sure given the expected interest, I may have to get this initially on the open market.
Are there any things from a finance view we should be aware of with these IPO's other than biotechs can be more risky dependent on clinical trial results, etc..
Repare has done well since its IPO in June.
Can you pls also add Repare to your db? It did not come up in a text or stock symbol search.

Cheers,
SteveMc
Read Answer Asked by Stephen on December 08, 2020
Q: Hi Peter, re: your reply to Jamie re: GUD; why will earnings fall next year ? Aren't they currently close to zero ? Shouldn't the new mfg ability increase earnings ?
This is currently the sole loser in my portfolio (as I'm getting good at cutting losses before they get worse) but like many I've held on it to doggedly for years despite its chart since I really want Jonathan G to do well. There's definitely a lesson in that. Thanks, Paul
Read Answer Asked by Paul on December 08, 2020
Q: Hi Gents,

Wondering if you could speak to the value of GUD shares.
My calculations are that there is $3.31/sh in cash, which at Friday's price of $5.29, leaves $1.98 for the rest of company.
At $1.98 the company ex cash is worth about $260M. My modeling shows a forward P/E ex cash below 8x. Plus you get the potential of another game-changing acquisition which would likely be very accretive.

What am I missing here at $5.30/sh??
Read Answer Asked by JAIME on December 07, 2020
Q: Hello: Is there any news on Canadian Companies that will be involved in potential COVID 19 vaccine management and delivery? Thanks!
Read Answer Asked by John on December 07, 2020
Q: Hi I am a holder of CVS. Within the past few weeks the price has risen sharply from mid-60.00 to 72.00 range on 2 occasions. First time was on vaccine news but dropped sharply a few days later on Amazon announcement of online drug sales. Within the past week it’s back today at 72.52. Are there underlying fundamentals to take it higher, and/or do you think their “full service” health service model will be involved with the vaccine rollout and administration and hence share price continue to move higher? Thanks
Read Answer Asked by Robert on December 04, 2020
Q: I submitted a question on this company, previously known as CB2 Insights (ticker: CBII), but not sure if it’s still in the queue or got missed. Sending it again just in case.

What are your thoughts on their recent earnings report and overall outlook?

Their primary business currently is providing subscription healthcare. I find it interesting that they’re a Canadian company running clinics entirely in the US. They claim profits are much easier to attain with US clinics as they don’t need to share revenue with the physicians. The doctors are only paid a salary.
Read Answer Asked by Laxmyharan on December 03, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!